Lademirsen - Novartis
Alternative Names: Lademirsen sodium; RG 012; RG 456070; SAR 339375Latest Information Update: 01 Jul 2025
At a glance
- Originator Regulus Therapeutics; Sanofi
- Developer Novartis; Regulus Therapeutics
- Class Antisense oligoribonucleotides; MicroRNAs; Urologics
- Mechanism of Action MicroRNA inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hereditary nephritis
Most Recent Events
- 25 Jun 2025 Regulus Therapeutics has been acquired and merged into Novartis
- 07 Apr 2023 Sanofi terminates its R & D agreement with Regulus Therapeutics for Lademirsen
- 28 Jul 2022 Discontinued - Phase-II for Hereditary nephritis in USA, Spain, Germany, France, China, Canada, Australia, United Kingdom (SC) as of July 2022